Lars Harbaum
Overview
Explore the profile of Lars Harbaum including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
883
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harbaum L, Hennigs J, Pott J, Ostermann J, Sinning C, Sau A, et al.
Am J Respir Crit Care Med
. 2024 Oct;
PMID: 39374572
Rationale: While sex differences in right heart phenotypes have been observed, the molecular drivers remain unknown. Objectives: To provide biological insights into sex differences in the structure and function of...
2.
Pott J, Csengeri D, Ostermann J, Klose H, Sinning C, Harbaum L
ERJ Open Res
. 2024 Jul;
10(4).
PMID: 38978554
https://bit.ly/4cRtREC.
3.
Klose H, Harbaum L, Richter M, Lichtblau M, Marra A, Kabitz H, et al.
Pneumologie
. 2023 Nov;
77(11):890-900.
PMID: 37963478
The 2022 guidelines on pulmonary hypertension from the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) provide therapeutic strategies that account for the variability in the clinical...
4.
Eichstaedt C, Bikou O, Sommer N, Schermuly R, Pullamsetti S, Weissmann N, et al.
Pneumologie
. 2023 Nov;
77(11):862-870.
PMID: 37963476
The recently published new European guidelines for diagnosis and treatment of pulmonary hypertension now offer the so far most extensive description of genetic testing and counselling for pulmonary arterial hypertension...
5.
Ostermann J, Pott J, Hennigs J, Roedl K, Sinning C, Harbaum L, et al.
ERJ Open Res
. 2023 Jun;
9(3).
PMID: 37260464
Background: The 2022 ESC/ERS guidelines on pulmonary hypertension recommend noninvasive risk assessments based on three clinical variables during follow-up in patients with pulmonary arterial hypertension (PAH). We set out to...
6.
Dittrich A, Mienert J, Pott J, Engels L, Sinning C, Hennigs J, et al.
ERJ Open Res
. 2023 Mar;
9(2).
PMID: 36923572
Background: Converging evidence from proteogenomic analyses prioritises thrombospondin-2 (TSP2) as a potential biomarker for idiopathic or heritable pulmonary arterial hypertension (PAH). We aimed to assess TSP2 levels in different forms...
7.
Korbelin J, Klein J, Matuszcak C, Runge J, Harbaum L, Klose H, et al.
Front Cardiovasc Med
. 2023 Jan;
9:1036096.
PMID: 36684555
Pulmonary arterial hypertension (PAH) is a disease characterized by elevated pulmonary vascular resistance and pulmonary artery pressure. Mortality remains high in severe cases despite significant advances in management and pharmacotherapy....
8.
Pott J, Grafin Zu Reventlow P, Simon M, Steurer S, Harbaum L, Henes F, et al.
Pneumologie
. 2022 Sep;
76(9):633-638.
PMID: 36104018
Pulmonary angiosarcoma is a rare and malignant disease of the blood vessels. Initially, it can be misdiagnosed as chronic thromboembolic hypertension (CTEPH). In CTEPH, there is increased pressure and resistance...
9.
Hennigs J, Huwe M, Hennigs A, Oqueka T, Simon M, Harbaum L, et al.
Infection
. 2022 May;
50(5):1391-1397.
PMID: 35570238
Purpose: Symptoms often persistent for more than 4 weeks after COVID-19-now commonly referred to as 'Long COVID'. Independent of initial disease severity or pathological pulmonary functions tests, fatigue, exertional intolerance...
10.
Harbaum L, Rhodes C, Wharton J, Lawrie A, Karnes J, Desai A, et al.
Am J Respir Crit Care Med
. 2022 Apr;
205(12):1449-1460.
PMID: 35394406
Pulmonary arterial hypertension (PAH) is characterized by structural remodeling of pulmonary arteries and arterioles. Underlying biological processes are likely reflected in a perturbation of circulating proteins. To quantify and analyze...